Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001085206 | SCV000554690 | likely benign | Multiple endocrine neoplasia type 4 | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000575706 | SCV000673209 | likely benign | Hereditary cancer-predisposing syndrome | 2017-03-10 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV000471828 | SCV001148643 | likely benign | not provided | 2024-06-01 | criteria provided, single submitter | clinical testing | CDKN1B: BP4, BP7 |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000471828 | SCV004220768 | likely benign | not provided | 2023-04-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003902661 | SCV004725283 | likely benign | CDKN1B-related disorder | 2020-10-15 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |